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Available online 13 December 2018Background: Excitatory amino acid transporter 2 (EAAT2) plays a pivotal role in glutamate clearance in the adult
brain, thereby preventing excitotoxic effects. Considering the high efficacy of EAAT2 for glutamate uptake,we hy-
pothesized that the expression of this transporter inmesenchymal stem cells (MSCs) for systemic administration
could yield a cell-based glutamate-grabbing therapy, combining the intrinsic properties of these cells with
excitotoxic protection.
Methods: To address this hypothesis, EAAT2-encoding cDNA was introduced into MSCs and human embryonic
kidney 293 cells (HEK cells) as the control cell line. EAAT2 expression and functionality were evaluated
by in vitro assays. Blood glutamate-grabbing activity was tested in healthy and ischemic rat models treated
with 3 × 106 and 9 × 106 cells/animal.
Findings: The expression of EAAT2 in both cell types conferred the expected glutamate-grabbing activity in in vitro
and in vivo studies. The functional improvement observed in ischemic rats treated with EAAT2–HEK at low dose,
confirmed that this effect was indeed mediated by the glutamate-grabbing activity associated with EAAT2 func-
tionality. Unexpectedly, both cell doses of non-transfected MSCs induced higher protection than transfected
EAAT2–MSCs by another mechanism independent of the glutamate-grabbing capacity.
Interpretation: Although the transfection procedure most likely interferes with some of the intrinsic protective
mechanisms of mesenchymal cells, the results show that the induced expression of EAAT2 in cells represents a
novel alternative to mitigate the excitotoxic effects of glutamate and paves the way to combine this strategy
with current cell therapies for cerebral ischemia.








Mesenchymal stem cells1. Introduction
Ischemic stroke, resulting from the interruption of blood supply to
the brain, is one of the most frequent causes of morbidity andmortality
worldwide [1]. During the acute phase of stroke, glutamate homeostasis
is disrupted, and glutamate levels rise above physiological concentra-
tions in the extracellular fluid. This pathological situation leads to an
overstimulation of glutamate receptors, followed by the excitotoxic
death of neurons [2,3]. Under physiological conditions, once glutamateT. Sobrino),
ako, Saitama 351-0198, Japan.
. This is an open access article underis released from excitatory neurons upon an action potential, the con-
centration of extracellular glutamate is tightly regulated by integral
membrane electrogenic transporters, known as excitatory amino acid
transporters (EAATs) [3]. Five subtypes of EAATs have been identified
and characterized thus far [4]. Among these, the EAAT2 protein, which
is mainly expressed in astroglial cells, is responsible for 90% of total glu-
tamate uptake, thereby preventing neuronal excitotoxicity. Inside the
astrocytes, glutamate is metabolized to glutamine or used for energy
production. Glutamine is subsequently transferred to neurons for the
replenishment of the glutamate pool via the glutamate–glutamine
cycle [2,5,6].
The expression of EAAT2 has also been described on the antiluminal
surface, i.e., the parenchymal side, of brain capillary endothelial cells.
Here, the transporter assists in maintaining low glutamatethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Ischemic stroke is a major cause of morbidity andmortality world-
wide. During the acute phase of stroke, glutamate homeostasis is
disrupted, and glutamate levels rise above physiological concen-
trations in the extracellular fluid. This pathological situation leads
to an overstimulation of glutamate receptors, followed by the
excitotoxic death of neurons. In brain, excitatory amino acid trans-
porters (EAATs) maintain the balance between pathological and
physiological conditions by limiting the extracellular concentration
of glutamate within the brain and thus preventing excitotoxic ef-
fects. Five genes have been identified in mammals encoding
EAATs. Of these, EAAT2 plays a pivotal role for glutamate clear-
ance in the adult brain. The critical role of EAAT2 in controlling
brain glutamate homeostasis has led to the development of differ-
ent therapeutic strategies to reduce the excitotoxic damage by
glutamate after stroke.
Added value of the study
Mesenchymal stem cells are currently the most promising candi-
dates for stem cell therapy against ischemic stroke owing to
their intrinsic capability to secrete growth factors and immuno-
modulatory cytokines. Based on the high efficacy of EAAT2 for
glutamate uptake, we hypothesized that the induced expression
of this membrane transporter in mesenchymal stem cells for sys-
temic administration could lead to a cell-based glutamate-
grabbing therapy, combining the intrinsic properties of these
cells with the excitotoxic protection.
Implications of all the available evidence
Here, and for first time, we found that this cell-based therapy,
using the administration of EAAT2-expressing cells for ischemic
lesions, could serve as a novel alternative to reduce glutamate
neuronal excitotoxicity. We believe that our study makes a signif-
icant contribution to the literature because this new strategy
paves the way to devise promising cell therapies for cerebral
ischemia.
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brain-to-blood glutamate efflux mechanism [7,8]. When the concentra-
tion of glutamate in the extracellular fluid is elevated, glutamate is ac-
tively transported unidirectionally via the endothelial EAAT2 into the
endothelial cells, where it is accumulated until it overrides the blood
concentration. Finally, glutamate is transported across the luminal
membrane into the blood by facilitated diffusion [7,9,10]. Therefore,
while blood glutamate may enter into endothelial cells, it can no go fur-
ther, as no transport of glutamate is possible from endothelial cells into
the brain [11].
The transport of glutamate by EAAT2 from the extracellularfluid into
either astrocytes or endothelial cells is an unfavorable and energy-
consuming process. This energy is provided by a coupled co-transport
of three sodium ions, one proton, and one glutamate molecule in the
counter-transport of one potassium ion. Notably, the transporters also
function as anion-selective channels [4].
The critical role of EAAT2 in controlling brain glutamate homeostasis
has led to the development of different therapeutic strategies to reduce
the excitotoxic damage by glutamate after stroke. β-lactam antibiotics
such as ceftriaxone have been described to be transcriptional activators
of EAAT2. Due to the increase in EAAT2 gene expression and transportactivity, treatment with antibiotics results in facilitated glutamate up-
take by astroglial cells and thus neuronal protection against ischemic in-
sult [3,5].
The brain-to-blood glutamate efflux mechanismmediated by endo-
thelial EAAT2 has also permitted the development of a new generation
of protective drugs against ischemic glutamate toxicity, namely, blood
glutamate-grabbers. These blood glutamate-grabbers can metabolize
and thus reduce the glutamate concentration in the blood. This leads
to a larger glutamate gradient between the brain and blood, facilitating
the efflux of extracellular brain glutamate via endothelial cells into the
blood. In the blood, glutamate is metabolized by the activity of gluta-
mate oxaloacetate transaminase 1 (GOT1), which catalyzes the trans-
formation of oxaloacetate and glutamate into aspartate and α-
ketoglutarate. Thus, the administration of both oxaloacetate and/or re-
combinantGOT1 (rGOT1) in ischemic animalmodels reduces glutamate
in both the blood and the brain, which improves functional recovery
after an ischemic lesion [9,12–17]. The protective efficacy of this strat-
egy has been shown in different types of ischemic animal models and
has been validated in humans by pharmacological [18] and non-
pharmacological approaches such as peritoneal dialysis [19]. It has
also been tested in other pathological models associated with an in-
crease in glutamate in the brain, such as traumatic brain injury [20], sub-
arachnoid hemorrhage [21], glioma [22], amyotrophic lateral sclerosis
[23], or Alzheimer's disease [24], with successful results.
On the basis of the substantial increase in glutamate uptake in astro-
cytes by the overexpression of EAAT2 and the promising efficacy of the
brain-to-blood glutamate efflux mechanism [3,9], we hypothesized
that combining EAAT2 expression in therapeutic cells for systemic ad-
ministration might accomplish an alternative cell-based glutamate-
grabbing therapy, i.e., by combining certain intrinsic cell properties
with excitotoxic protection.
Therefore, EAAT2-encoding cDNA was introduced and functionally
expressed in mesenchymal stem cells (MSCs), which are among the
best candidates for stem cell therapy for ischemic stroke owing to
their ability to release growth factors, as well as their immunomodula-
tory capacities [25]. For independent control experiments, EAAT2 was
introduced into human embryonic kidney 293 (HEK 293) cells, which
do not interfere with ischemic damage per se. The expression and func-
tionality of EAAT2 in both cell types were evaluated by several in vitro
assays, and the blood glutamate-grabbing activity was tested in ische-
mic animals and compared with that resulting from oxaloacetate
treatment.2. Experimental procedures
2.1. Culture of MSCs
Commercially available rat MSCs (Trevigen; Cultrex, Gaithersburg,
MD, USA) were cultured in a medium consisting of Iscove's modified
Dulbecco's medium (Gibco-Invitrogen, Waltham, MA, USA) supple-
mented with 10% fetal bovine serum (FBS; Gibco-Invitrogen), 10%
horse serum (Gibco-Invitrogen), 1% penicillin-streptomycin (PS;
Gibco-Invitrogen), and 1% antimycotic solution (amphotericin; Sigma-
Aldrich, St. Louis, MO, USA). The cells were maintained at 37 °C in a hu-
midified atmosphere and 5% CO2.2.2. Culture of HEK 293 cells
HEK 293 cells obtained from ECACC (Sigma-Aldrich, Taufkirchen,
Germany) were cultured in minimum essential medium (MEM)
GlutaMAX I (Gibco-Invitrogen) supplemented with 10% FBS, 1% MEM
non-essential amino acids (Gibco-Invitrogen), 1% PS, and 1%
amphotericin. The cells weremaintained at 37 °C in a humidified atmo-
sphere and 5% CO2.
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To functionally express EAAT2 in MSCs and HEK cells, we generated
recombinant adeno-associated virus serotype 2 (rAAV2) harboring the
coding sequence for yellow-fluorescent protein (YFP) N-terminally
fused in-frame to the coding sequence of EAAT2. We observed good
transduction rates in HEK cells (≥50%) but rather low efficiencies in
MSCs (approximately 5–10%). Changing the AAV serotype from AAV2
to AAV6 did not overcome the low transduction rate inMSCs. Therefore,
we changed the expression strategy and used a plasmid containing the
N-terminally YFP-tagged EAAT2 cDNA (pRcCMVmYFPEAAT2) for cell
transfection (see Fig. S1).
YFP-EAAT2 expression in MSCs was achieved using an electropora-
tion method as previously described [26]. For electroporation, cells
were resuspended in Human MSC Nucleofector Solution (Amaxa
Biosystems, Cologne, Germany) at a concentration of 1 × 106 cells/100
μL. The cell suspension was mixed with 4 μg endotoxin-free plasmid
DNA in a sterile electroporation cuvette (Amaxa Biosystems) and
electroporated with the U-23 program. After electroporation, the cells
were incubated for 5 min at RT and then transferred to culture dishes
pretreated with poly-D-lysine (Sigma-Aldrich) containing prewarmed
growthmedium. After 24 h, themediumwas changed to remove debris
and dead cells.
For the expression of YFP-EAAT2 in HEK cells, the plasmid was
transfected using calcium phosphate co-precipitation according to the
protocol described by Chen and Okayama [27]. Since the plasmid con-
tains a neomycin resistance gene, stably transfected cells were selected
in medium containing 1.2 mg/mL geneticin (G-418; Gibco-Invitrogen).
Antibiotic-resistant colonies were isolated and maintained in culture
medium supplemented with 1 mg/mL G-418 and examined for homo-
geneity based on YFP fluorescence.
Viral transduction and plasmid transfection methods are described
in detail in the Supporting Information.
2.4. Assessment of YFP-EAAT2 expression in MSCs and HEK cells
The expression of YFP-tagged EAAT2was evaluated and quantified at
24, 48, and 72 h post transfection using fluorescence microscopy and
flow cytometry, respectively. Fluorescence microscopy was performed
with an Olympus microscope, model IX51 (Olympus, Shinjuku, Tokyo,
Japan). In the flow cytometry analysis, 30,000 gated events (cells)
were collected. A cell was considered positive for YFP expression
when its fluorescence was higher than the threshold settings of the
non-transfected control sample. The percentage of YFP-fluorescent
cells was calculated with respect to the total number of cells. Flow cy-
tometry analysis was performedwith a FACSAria II analyzer (BD Biosci-
ences, Franklin Lakes, NJ, USA), and data were analyzed with the
FACSDiva software program (BD Biosciences).
2.5. Immunostaining of EAAT2 in transfected MSCs and HEK cells
Cells were grown on glass coverslips, whichwere previously treated
with 0.1 mg/mL poly-D-lysine hydrobromide (Sigma-Aldrich). Cells
were rinsed with phosphate buffered saline (PBS) and fixed in 4%
(w/v) paraformaldehyde (PFA) solution (Thermo Fisher Scientific, Wal-
tham, MA, USA) for 5 min at room temperature (RT), and then washed
thrice with PBS. Non-specific binding sites were blocked with 0.5%
(w/v) bovine serumalbumin (BSA) (GEHealthcare, Chicago, IL, USA) so-
lution for 30min at RT. Cells were incubatedwith anti-EAAT2 antibodies
(Millipore, Burlington, MA, USA) diluted 1:100 in 0.5% (w/v) BSA in PBS
solution for 24 h at 4 °C. Cells werewashed thricewith PBS at RT and in-
cubated with a biotinylated horse anti-mouse IgG antibody, rat
adsorbed (dilution 1:200; Vector Laboratories, Burlingame, CA, USA),
for 1 h at RT, followed by a second incubation with a 1:100 dilution of
avidin–biotin (Vector Laboratories) for 30 min. Once washed, the sam-
ples were incubated with DyLight 594 streptavidin (diluted 1:500 inPBS; Vector Laboratories) for 30min at RT, followed by a last incubation
step with Hoechst stain (diluted 1:6000; Invitrogen) for 5 min. Fluores-
cence was analyzed with a confocal microscope (LEICA AOBS-SP5X;
Leica, Wetzlar, Germany).
2.6. Characterization of transfected MSCs
Flow cytometry, tube formation assay, and growth factor release
analysis were performed to verify that the transfectedMSCsmaintained
their intrinsic phenotype properties.
Flow cytometry analysis: MSCs were harvested using trypsinization,
washed, and resuspended in PBS. The typical phenotype of MSCs is
CD90+/CD73+/CD45−. Cells were stained with CD90-PerCP-Cy5
(clone OX-7; 5 μL/1 × 105 cells; Immunostep, Salamanca, Spain),
CD73-APC (clone 5F/B9; 1 μL/1 × 105 cells; Immunostep), and CD45-
PE (clone OX-22; 2.5 μL/1 × 105 cells; BD Biosciences) antibodies.
After immunostaining, the cells were suspended in 200 μL PBS for sub-
sequent analysis. The analysis was performed using a BD FACSAria II an-
alyzer (BD Biosciences). Unlabeled MSCs were used as a negative
control. Dead cells and debris were excluded based on side and forward
scatter profiles (SSC and FSC, respectively). Appropriate isotype control
antibodies, “fluorescence minus one” staining, and staining of negative
populations were used to establish compensation parameters and
sorting gates. Data were analyzed using FACSDiva software (BD
Biosciences).
Tube formation assay: Matrigel-reduced growth factor (BD Biosci-
ences) was used as a substrate to assess tube formation capacity as an
in vitro measurement of functional angiogenesis in non-transfected
MSCs (MSCs−) and transfectedMSCs (MSCs+). Standard 24-well plates
were coatedwith 200 μL coldmatrigel.MSCswere added ontomatrigel-
coated wells at 1 × 104 cells per well in growth medium. Cells were in-
cubated for 12 h at 37 °C and 5% CO2 in a humidified atmosphere. After
medium removal, cells were fixed in 4% (w/v) PFA in PBS, and images
were captured using an invertedmicroscope (Olympus IX51). Tube for-
mation was assessed by counting the number of circular structures
(rings) and branching points (tube joints). Five random fields were ex-
amined for each well.
Vascular endothelial growth factor (VEGF) analysis in cell culture su-
pernatants: The levels of VEGF in MSCs− and MSCs+ were measured
with a Quantikine VEGF ELISA kit (R&D Systems, Minneapolis, MN,
USA) following the manufacturer's instructions. The detection limit
was 31.2 pg/mL (VEGF ELISA kit), and values were corrected for the
amount of total cell protein calculated by the Bradford assay (Bio-Rad,
Hercules, CA, USA).
2.7. Analysis of interleukin-6 production in MSCs after transfection and li-
popolysaccharide treatment
Non-electroporated and electroporated MSCs (without plasmid and
with control and EAAT2-plasmid), were seeded in culture dishes
pretreated with poly-D-lysine (Sigma-Aldrich). After 24 h, the medium
was removed, and it was replaced with fresh medium containing lipo-
polysaccharide (LPS) (1 μg/mL; Sigma-Aldrich) [28]. The supernatants
were harvested by centrifugation at 3000 rpm for 20 min and stored
at−80 °C until further use. The levels of interleukin-6 (IL-6) weremea-
sured with an IL-6 ELISA kit (Abbexa, Cambridge, UK) following the
manufacturer's instructions. The detection limit was 3.3 pg/mL (IL-6
ELISA kit), and valueswere corrected for the amount of total cell protein
calculated by the Bradford assay (Bio-Rad). The plasmid encoding the
fluorescent protein eGFP (pmaxGFP) was used as the control (VPE
1001; Lonza, Basel, Switzerland).
2.8. Glutamate uptake assay
The uptake of radiolabeled glutamate was assessed using a competi-
tion assay. Transfected cells (HEK+ cells and MSCs+) expressing EAAT2
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ture plates pre-treated with poly-D-lysine hydrobromide (Sigma-Al-
drich). Non-transfected cells (HEK− and MSCs−) were used as the
negative control, and astrocytes were employed as the positive control.
After 24 h, the medium was aspirated, and cells were washed thrice
with 250 μL PBS at RT. Then, 500 μL PBS supplemented with 13 nM
L-[3H]glutamate (1 μCi/μL; Sigma-Aldrich; specific activity = 51.1 Ci/-
mmol) and increasing concentrations (10−8–10−3 M) of non-labeled
glutamate were added. Non-labeled glutamate was added to each
well, and the plate was incubated at 37 °C for 10 min. The plates were
placed on ice, and cells were washed thrice with ice-cold PBS. Cells
were lysed with 200 μL 0.2 M NaOH for 4 h at 4 °C under continuous
shaking. From each lysate, 50 μL was transferred to a 96-well multiplex
plate, and 150 μL Optiphase buffer was added to each well. The multi-
plex plate was shaken for 30 min at RT. Radioactivity was determined
by scintillation counting (PerkinElmer, Waltham, MA, USA), and the
total protein content in lysates was determined by the Bradford assay
(Bio-Rad). The results were expressed in radioactive disintegrations
per minute per microgram of cellular protein.
To determine the specificity of glutamate uptake, two inhibitors of
EAAT2—dihydrokainate (DHK) and DL-threo-beta-benzyloxyaspartate
(TBOA) (Tocris, Bioscience, Avonmouth, Bristol, UK)—were employed.
Both inhibitors were used individually and jointly at concentrations of
300 μM (DHK) and 500 μM (TBOA) based on previous studies [8].
2.9. In vitro toxicity test
Cell death was evaluated by measuring the leakage of lactate dehy-
drogenase (LDH) into the medium, as well as the cell proliferation
rate. Basal LDH and LDH release at 24, 48, and 72 h after transfection
were measured in control and transfected cells. A negative control of
lysed cells was also included (death control), according to themanufac-
turer's protocol. After centrifugation (7 min, 3000 rpm) of the superna-
tants, 75 μL was transferred in a 96-well plate and mixed with 150 μL
LDH reagents following the manufacturer's protocol (Lactate Dehydro-
genase Assay Kit; Sigma-Aldrich). After 20 min incubation at RT, the
LDH activity was determined at 490 nm using a spectrophotometer
(Synergy 2; BioTek, Winooski, VT, USA).
2.10. Proliferation rate
To determine the proliferation rate, the total cell number was exam-
ined using a Neubauer chamber. The number of viable cells was deter-
mined using the Trypan blue exclusion assay.
2.11. Experimental animals
Experimental protocols were approved by the local Animal Care
Committee according to the European Union (EU) rules (86/609/CEE,
2003/65/CE, and 2010/63/EU). Male Wistar rats (Harlan Laboratories,
Barcelona, Spain) weighing 300 ± 25 g were used. The animals were
kept at controlled conditions of temperature (22 °C± 1 °C) and humid-
ity (60% ± 5%) with a 12/12 h light/dark cycle for a week prior to sur-
gery and up to 14 days after surgery. Rats had access to food and
water ad libitum. Anesthesia was induced by the inhalation of 5%
sevoflurane in a nitrous oxide/oxygenmixture (70/30). Rectal tempera-
ture was monitored and maintained at 37 °C ± 0.5 °C by using a
feedback-controlled heating system. Glucose levels were found to be
100–180 mg/dL before surgery. At the end of the procedures, rats
were sacrificed under deep anesthesia (8% sevoflurane).
2.12. Surgical procedures
Transient focal ischemia was induced in rats by transient middle ce-
rebral artery occlusion (MCAO) following previously described surgicalprocedures [12,29]. According to our reported protocol [29], the follow-
ing exclusion criteria were used: (i) b70% reduction in relative cerebral
blood flow during artery occlusion; (ii) arterialmalformations, as deter-
mined bymagnetic resonance angiography; (iii) baseline lesion volume
of b25%or N 45%with respect to the ipsilateral hemisphere, asmeasured
using apparent diffusion coefficient (ADC)maps; and (iv) absence of re-
perfusion or prolonged reperfusion (N10 min until achievement of at
least 50% of the baseline cerebral blood flow) after filament removal.
All excluded or deceased animals were replaced until the total number
of animals indicated for each group was attained. Additional details of
the surgical procedures are indicated in the Supporting Information.
2.13. In vivo experimental protocol
This study was divided into two steps: a dose-response study and a
protective study.
Dose-response study: different doses of MSCs+ and HEK+ cells were
evaluated for blood glutamate reduction after i.v. administration and
compared with the same dose of non-transfected cells (MSCs− and
HEK−) with an oxaloacetate-treated group and a control group treated
with saline.
Protective study: To evaluate the protective effect of MSCs+ and
HEK+ cells against ischemic lesions, transfected cells were tested in is-
chemic animal models, and their effect on blood glutamate reduction,
infarct volume, and functional recovery was compared with the effect
of the administration of non-transfected cells (MSCs− and HEK−)
with oxaloacetate and with that of a control group treated with saline.
The experimental groups, glutamate and IL-6 analysis in blood sam-
ples and functional test are summarized in the Supporting Information.
2.14. Magnetic resonance studies
All magnetic resonance imaging (MRI) studies were conducted on
a 9.4 T horizontal bore magnet (Bruker BioSpin, Ettlingen, Germany)
according to a previously described protocol [16,29,30]. MRI post-
processing was performed using ImageJ software (https://imagej.nih.
gov/ij/). Additional details about MRI sequences and data analysis are
described in the Supporting Information.
2.15. Brain histological analysis
Animals were sacrificed 14 days after surgical treatment, and brain
tissue was processed for histological analysis. Neuronal nuclear protein
(NeuN) labeling was combined with labeling of the astrocyte marker;
glial fibrillary acidic protein (GFAP). GFAP-positive and NeuN-positive
cells and nuclei were counted manually in Image J software. Detailed
protocols are described in the online Supporting Information.
2.16. Statistical analysis
All data are presented as themean± standard deviation of themean
(mean ± SD). One-way or two-way analysis of variance (ANOVA)
followed by post-hoc Bonferroni evaluation was used for multiple
groups to determine significant differences. Student's t-test was used
to test the differences between two groups. Statistical significance was
set at *p b 0.05, **p b 0.01, and ***p b 0.001. The statistical analysis
was conducted using GraphPad Prism v.6.05 for Windows (GraphPad,
La Jolla, CA, USA).
3. Results
3.1. EAAT2 expression in MSCs and HEK 293 cells
EAAT2 was initially expressed in MSCs and HEK 293 cells by rAAV2
transduction. However, we did not achieve sufficient transduction
rates (≥30%) in MSCs (see supplemental results and Figs. S2 and S3),
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three different transfectionmethodswere consecutively tested: calcium
phosphate co-precipitation, lipofectamine transfection, and electropo-
ration (With electroporation, we obtained successful and reliable
expression rates of ≥60%).
Since the construct coded for an N-terminally YFP-tagged EAAT2
protein, successful expression of the fusion protein in MSCs (MSCs+)
could bemonitored by confocalmicroscopy (Fig. 1A). Usingflowcytom-
etry analysis, maximum cells (≥60%) expressing the YFP-EAAT2 protein
were observed 48 h after transfection (Fig. 1B). No YFP expression was
detected inMSCs electroporatedwithout the plasmid (MSCs−). To eval-
uate thepotential cell damage induced by electroporation,MSCprolifer-
ation and toxicity rates were determined. Notably, electroporation
caused a significant (p b 0.05) reduction in MSC+ proliferation 24 and
48 h after transfection compared to MSCs−. This effect, however, was
not observed 72 h after electroporation (Fig. 1C). Toxicity analysis was
performed by LDH assay. There were no significant differences between
MSCs+ and MSCs− (Fig. 1C, lower panel). Finally, confocal microscopy
confirmed the expression of YFP-EAAT2 in MSCs+ (Fig. 1D, E), with a
preferential localization in the cell membrane (Fig. 1D).
In addition to MSCs, HEK 293 cells were transfected with the same
plasmid using the calcium phosphate co-precipitation technique [27].
Since the plasmid harbors a neomycin resistance gene, stably
transfected cell clones constitutively expressing YFP-EAAT2 (HEK+)
were selected andmaintained in the presence of the antibiotic geneticin
(G418). The expression of the construct in HEK+ cells was inspected by
confocal microscopy (Fig. 2A). Flow cytometry showed that the initial
transfection efficiency was ≥50% (Fig. 2B). In contrast to electroporation
used for MSCs, calcium phosphate co-precipitation did not have an im-
pact on the proliferation rate or toxicity of cells transfected without
(HEK−) or with the plasmid (HEK+) (Fig. 2C). Selection with geneticin
resulted in the isolation of cell clones that homogeneously (≥95%)
expressed the construct (Fig. 2D, E).
Summary of the procedures used to induce the expression of EAAT2
in MSCs and in HEK cells is represented in Fig. S4.3.2. Functional analysis of EAAT2 in MSCs
+ and HEK+ cells
To evaluate the functionality of EAAT2 expressed in both cell types,
uptake assays with [3H]glutamate were conducted in MSCs+ and
HEK+ cells. For the control, assays were also performed in primary as-
trocytes that are known to express EAAT2 endogenously [3]. The uptake
of [3H]glutamate (13 nM) in astrocytes was determined in the presence
of increasing concentrations of unlabeled glutamate (10−8–10−3 M).
The uptake of [3H]glutamate was significantly reduced (EC50 = 19
μM), and the concentration-response curve saturated at glutamate con-
centrations of ≥5 × 10−4 M. The uptake of [3H]glutamate was alsomea-
sured in the presence of specific inhibitors of glial EAAT2 activity [8,31]:
TBOA and DHK. We found that 500 μM DHK and 300 μM TBOA effi-
ciently inhibited the [3H]glutamate uptake in astrocytes (see Fig. S5).
The incubation of MSCs+ with 13 nM [3H]glutamate in the presence
of increasing amounts of non-labeled glutamate (10−8–10−3 M)
showed specific glutamate uptake. The competitive effect was saturated
at concentrations of ≥5×10−4Mof non-labeled glutamate, and the EC50
calculated from the concentration-response curvewas65 μM. InMSCs−,
no specific uptake of [3H]glutamate was detected (Fig. 3A). Glutamate
uptake in MSCs+ was abolished when TBOA (300 μM) and DHK (500
μM) were included in the assay either in combination (Fig. 3B) or indi-
vidually (p b 0.001) (Fig. 3C). Glutamate uptake experiments were per-
formed in a similarmanner on HEK+ cells. As observed inMSCs+, HEK+
cells showed a specific [3H]glutamate uptake with a similar EC50 (62
μM) as that determined for MSCs+. No specific [3H]glutamate uptake
was observed in HEK− cells (Fig. 3D). [3H]glutamate uptake into
HEK+ cells was blocked when EAAT2 inhibitors (TBOA and DHK) were
added together (Fig. 3E) or separately (p b 0.001) (Fig. 3F).3.3. Phenotype evaluation of MSCs+
Some of the most important characteristics contributing to the ben-
eficial effects of MSCs in stroke are their angiogenic properties, as well
as their capability to act as a source of growth factors and cytokines
[32]. Here,we evaluatedwhether EAAT2 expressionmodified the intrin-
sic characteristics of MSCs+ and determined their angiogenic capacity,
their capacity to secrete VEG, and the expression of membrane mesen-
chymal markers (CD90+, CD73+, and CD45−).
The angiogenic capacity of MSCs+ was examined by an in vitro
matrigel tube formation assay, confirming that the number of rings
identifiedwas similar to those obtainedwithMSCs− (Fig. 4A–C). The re-
lease of VEGF byMSCs+ andMSCs−was also similar (Fig. 4D). The anal-
ysis of membrane mesenchymal phenotype markers (CD90+, CD73+,
and CD45−) was performed by flow cytometry, which showed that
MSCs+ andMSCs− did not differ in surfacemarker expression (Fig. 4E).
3.4. Animals included in the study
Once the expression and functionality of EAAT2 was evaluated in
MSCs+ and HEK+ cells, their blood glutamate-grabbing activity was an-
alyzed first in healthy animals and then in ischemic animal models. A
total of 179 experimental animals (male Wistar rats) were used in this
study. Forty-eight rats were used to study the effect of MSCs+ and
HEK+ cells on blood glutamate-grabbing, and the remaining 131 were
used in the ischemic study. From these, 72 rats were excluded because
they did notmeet the inclusion criteria and 11 died; finally, 48 ischemic
rats were examined (Fig. S6).
3.5. Analysis of blood glutamate concentration in healthy animals treated
with MSCs+ and HEK+ cells
To evaluate the effect of MSCs+ and HEK+ cells on blood glutamate
reduction in healthy animals, a cell dose/response studywas performed
with i.v. administered 1 × 106, 2 × 106, and 3 × 106 cells/animal. A dose
of 3 × 106 cells/animal was necessary to obtain a reduction in glutamate
levels (Fig. 5A). Then, eight experimental groupswere designed to com-
pare the efficacy of the cells' glutamate-grabbing therapy on glutamate
reductionwith respect to oxaloacetate treatment. These groupswere as
follows: (i) a control group treated with saline (vehicle), (ii) a group
treated with oxaloacetate (35 mg/kg) [13] used as a positive control
for blood glutamate reduction, (iii) a group treated with 3 × 106 HEK−
cells, (iv) a group treated with 3 × 106 HEK+ cells, (v, vi) two groups
treated with 3 × and 9 × 106 MSCs−, and (vii, viii) two groups treated
with 3× and 9 × 106 MSCs+. Glutamate levels were determined before
cell administration (i.e., basal levels) and 1, 3, and 4 h after cell admin-
istration. All treatments were administered by i.v. bolus in 1 mL of
saline.
MSCs+ for animal treatment were taken 48 h after transfection (see
Fig. 1B). HEK+ cells were taken from the stably transfected cell clone
(see Fig. 2D). Blood glutamate concentrations in animals treated with
saline did not change significantly within the first 4 h after treatment.
Similarly, the groups of animals treated with non-transfected cells—
HEK− and MSCs−—did not show a significant reduction in blood gluta-
mate levels after treatment administration either. In linewith our previ-
ous results [13], oxaloacetate led to a reduction in glutamate at 1 h (p b
0.05) and 4 h (p b 0.05) after the administration of the compound. The
administration of 3 × 106 HEK+ cells resulted in a reduction in blood
glutamate levels 1 and 3 h after injection.With 3 × 106 MSCs+, a signif-
icant glutamate reductionwasmeasured 1 and 2 h after cell administra-
tion (p b 0.05, n=6/group) (Fig. 5B). A higher dose of MSCs+ (9 × 106)
did not increase the reduction in blood glutamate levels compared to
the values achievedwith 3 × 106MSCs+; however, the effect lasted lon-
ger and was detectable even 4 h after cell administration. Notably, the
treatment of rats with MSCs+ reduced the blood glutamate to a level
similar to that measured 4 h after oxaloacetate administration.
Fig. 1. Analysis of YFP-EAAT2 expression in MSCs. (A) Confocal image of control (MSCs−) and YFP-EAAT2-expressing MSCs (MSCs+) after electroporation (scale bar, 25 μm). (B) YFP
fluorescence in MSCs analyzed by flow cytometry: non-transfected cells (FITC) and transfected cells (FITC 24 h, FITC 48 h, and FITC 72 h) after transfection. (C) Analysis of the
proliferation rate and toxicity (measured by an LDH assay) of electroporated cells without plasmid (MSCs−) and with the YFP-EAAT2-encoding construct (MSCs+). Data shown are
normalized to MSC− levels (*p b 0.05, n = 3). (D) Immunocolocalization of YFP-EAAT2 in MSCs+ (scale bar, 10 μm). (E) Immunofluorescent labeling of nuclei (Hoechst, blue), YFP
(green), and EAAT2 (red) in control (MSCs−) and transfected MSCs+ (scale bar, 25 μm).
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Fig. 2. Analysis of YFP-EAAT2 expression in HEK cells. (A) Confocal image of YFP-EAAT2-expressing HEK cells after calcium phosphate transfection (scale bar, 25 μm). (B) YFP fluorescence
in HEK cells analyzed by flow cytometry: before and 48 h after transfection. (C) Analysis of proliferation rate and toxicity (measured by an LDH assay). Data are normalized to HEK− levels
(*p b 0.05, n= 3). (D) An HEK+ colony constitutively expressing YFP-EAAT2 (scale bar, 100 μm). (E) Immunofluorescent labeling of nuclei (Hoechst, blue), YFP (green), and EAAT2 (red).
Scale bar, 25 μm. Non-transfected HEK cells (HEK−); transfected HEK cells (HEK+).
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Fig. 3. Evaluation of glutamate uptake in MSCs+ and MSCs. (A) [3H]glutamate uptake in MSCs+ and MSCs in the presence of increasing concentrations of non-labeled glutamate.
(B) Inhibition of [3H]glutamate uptake mediated by the simultaneous application of DHK (300 μM) and TBOA (500 μM) in MSCs+. (C) Inhibition of [3H]glutamate uptake with both
inhibitors applied individually to MSCs+ (***p b 0.001, n = 6). (D) [3H]glutamate uptake assay in HEK+ and HEK− cells. (E) Selective inhibition of glutamate uptake mediated by the
simultaneous application of DHK and TBOA in HEK+ cells, and (F) inhibition of glutamate uptake with both inhibitors administered individually to HEK+ cells (***p b 0.001, n = 6).
Radioactivedisintegrationsperminute (DPM); protein (prot); DL-threo-beta-benzyloxyaspartate (TBOA); dihydrokainate (DHK); non-transfectedMSCs (MSC−); transfectedMSCs (MSC+).
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acetate treatment in ischemic animal models
Once the blood glutamate-grabbing efficacy in healthy ratswas eval-
uated, the protective effect of MSCs+ and HEK+ cells was tested in
ischemic rat models. No effect on blood glutamate reduction
was observed in the rats treated with saline and non-transfected cells
(3 × 106 HEK−, 3 × 106 MSCs−, and 9 × 106 MSCs−). Ischemic rats
treated with oxaloacetate and 3 × 106 HEK+ cells showed significant
reductions (p b 0.05, n = 6/group) in blood glutamate levels 1 h
after treatment. The effect lasted even longer (3–4 h) when 3 × 106 or
9 × 106 MSCs+ were administered (Fig. 6A).
MRI analysis during the occlusion revealed that all animals showed
similar ischemic lesions before the administration of cells oroxaloacetate (average ischemic lesion, 42%±4%, adjusted to the ipsilat-
eral hemisphere). Inspection of the infarct volume on day 14 showed
that oxaloacetate, 3 × 106 MSCs+, and interestingly, 3 × 106 and 9
× 106 of both MSC−-treated groups showed reductions in infarct vol-
ume (30.9% ± 5% vs. 24.3% ± 4%; 30.9% ± 5% vs. 25.4% ± 3%; 30.9%
± 5% vs. 22.7% ± 3%, and 30.9% ± 5% vs. 13.5% ± 11%; respectively, p
b 0.05, n = 6/group). A trend of reduced infarct volume was also ob-
served with 9 × 106 MSCs+, but this effect was not statistically signifi-
cant (Fig. 6B and C). Associated with the regression of the infarct
volume, a functional recovery of the rats occurred, whichwas examined
by the cylinder test. Notably, the administration of 3 × 106 HEK+ cells
also resulted in functional improvement (Fig. 6D).
Histological analysis of a neuronal marker (NeuN) and a glialmarker
(GFAP) performed 14 days after lesioning did not reveal expression
Fig. 4. Examination of MSC characteristics. Phase-contrast image of matrigel angiogenic assay in MSCs− (A) and MSCs+ (B), (scale bar, 100 μm). (C) Analysis of ring formation of MSCs−
and MSCs+. Data are shown as mean ± SD (n= 3). (D) VEGF release determined at different time-points in MSCs− and MSCs+. Data are shown as mean ± SD (n = 3). (E) Analysis of
mesenchymal phenotypemarkers (CD90+, CD73+, and CD45−) inMSCs− (upper panel) andMSCs+ (lower panel) by flowcytometry (n=3). Non-transfectedMSCs (MSC−), transfected
MSCs (MSC+), fluorescein isothiocyanate (FITC), allophycocyanin (APC), peridinin chlorophyll protein c complex (PerCP), phycoerythrin (PE), yellow fluorescent protein (YFP).
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Fig. 5. Analysis of cell glutamate in healthy rats. (A) Dose/response analyses of 1 × 106, 2 × 106, and 3 × 106 HEK+ cells and MSCs+/animal on blood glutamate levels 4 h after cell
administration. (B) Effect of the different treatments on blood glutamate concentration at distinct time-points in healthy animals. Data are normalized to basal glutamate levels (*p b
0.05, **p b 0.01, n = 6/group). The dashed line represents the 100% value of basal glutamate levels. Non-transfected MSCs (MSC−); transfected MSCs (MSC+); non-transfected HEK
cells (HEK−); transfected HEK cells (HEK+).
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any experimental group (Fig. S7). Interestingly, in the cortical region
(Fig. 6E), a higher (although not significant) neuronal survival rate
and smaller lesion scar were found in the groups treated with oxaloac-
etate, 3 × 106 MSCs−/MSCs+, and 9 × 106 MSCs−, i.e., where the infarct
volumehad also significantly regressed during the observation period of
14 days (Fig. 6F and G).3.7. EAAT2 expression in MSCs is associated with the release of IL-6
In an attempt to explain the lower protective effect of MSCs+ than
that of MSCs− in ischemic animals, we examined whether the transfec-
tion procedure could affect the release of IL-6, one of themost represen-
tative cytokines associated with the immunomodulatory function of
MSCs [25,33,34].
Analysis of IL-6 levels in the supernatants of MSC− and MSC+ cul-
tures 24 h after electroporation showed an increase in IL-6, from 2.0
± 0.2 pg/mL to 32.9 ± 8.5 pg/mL and 35.3 ± 9.5 pg/mL (p b 0.05) in
MSCs+ and MSCs−, respectively, whereas no change in IL-6 secretion
was detected in MSCs that had not been electroporated (MSCs). Cells
electroporated with a control plasmid also showed a release of IL-6
(2.5 ± 0.3 vs. 63.1 ± 8.5 pg/mL (p b 0.05).
Stimulation of non-electroporated MSCs and electroporated MSCs
with LPS, a proinflammatory agent, confirmed the intrinsic capacity of
MSCs to release IL-6 in response not only to mechanical stress (as elec-
troporation) but also to pro-inflammatory stimuli (Fig. 7A).
Analysis of IL-6 in blood samples from ischemic rats before (basal)
and after treatmentwith saline (vehicle) and 9×106MSCs− showed in-
creased IL-6 levels 24 h after ischemia regardless of whether vehicle or
cells were administered (vehicle: 7.5 ± 13 pg/mL vs. 45.6 ± 23 pg/mL;
MSCs−: 4.8±15pg/mL vs. 27.2±23 pg/mL, p b 0.05, Fig. 7B). However,
in line with the in vitro analysis (Fig. 7A), this increase was significantlyhigher in rats treated with 9 × 106 transfected cells (MSCs+: 3.8 ±
6 pg/mL vs. 89.0 ± 9 pg/mL; p b 0.05, Fig. 7B).
4. Discussion
Blood/brain glutamate-grabbing is an emerging protective strategy
to reduce the excitotoxic effect of the elevated extracellular glutamate
that accumulates in the brain during the acute phase of ischemic stroke
[9,18]. This novel protective strategy has been tested by several labora-
tories in different ischemic animal models [13,16,35–38], using the two
most common pharmacological approaches, i.e., oxaloacetate and
rGOT1 application. The protective mechanism has also been validated
by non-pharmacological approaches like peritoneal dialysis, used to fil-
ter the blood and remove excess glutamate [19,39,40]. All these studies
imply that blood glutamate reduction holds great potential as an effec-
tive protective strategy to reduce the neurotoxic increase in glutamate
in the brain. On the basis of the high specificity of excitatory amino
acid transporters, e.g., EAAT2, for glutamate uptake, we developed a
novel cell-based blood/glutamate-scavenging approach by introducing
the coding sequence of EAAT2 into MSCs, combining the intrinsic prop-
erties of these cells with excitotoxic protection. Here, we compared the
blood glutamate-grabbing efficacy of this cell-based strategy with the
“gold standard,” i.e., oxaloacetate treatment.
The transporter was successfully expressed in MSCs and HEK 293
cells. In both cell types, the expression of YFP-EAAT2 was confirmed by
immunological staining and flow cytometry. The functionality of the
transporter was determined by [3H]glutamate uptake assays, and the
blood glutamate-grabbing activity was validated in healthy rats. The re-
sults demonstrated that systemic administration of cells expressing
EAAT2 significantly reduces blood glutamate levels. The effect on blood
glutamate reduction produced by MSCs+ and HEK+ was very similar
to that resulting from oxaloacetate administration. The highest dose of
MSCs+ (9 × 106 cells) reduced the glutamate concentration for up to
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cells or oxaloacetate. It is tempting to speculate that a higher expression
level of EAAT2 or higher cell doses per animal could increase the
glutamate-grabbing efficacy. Here, as well as in previous studies
[26,27], the expression of EAAT2 in MSCs+ and HEK+ cells was techni-
cally optimized to gain high transporter levels per cell and simulta-
neously keep the cells healthy. We are aware that alternative
strategies, e.g., invoking lentivirus infection, may result in even higher
transduction rates, and this aspect should be addressed in forthcoming
studies. Regarding the cell dose used, we established 3 × 106 cells per
animal as a threshold necessary to induce a significant reduction in
blood glutamate levels. The risk of cell aggregation and pulmonary em-
bolism has been described in other studies [41]; therefore, to avoid the
death of the animals, doses higher than 9 × 106 MSCs+ were not used.
Owing to the lack of experience and literature on HEK cells for i.v. ad-
ministration and to reduce the risk of systemic embolisms, doses higher
than 3 × 106 cells were not tested.
The therapeutic effect of MSCs+ and HEK+ cells was thoroughly ex-
amined in ischemic rats and compared with that of oxaloacetate treat-
ment. In line with the results in healthy rats, the administration of
transfected cells and oxaloacetate significantly reduced blood glutamate
levels, which was associated with the functional recovery of the ani-
mals. However, oxaloacetate, 3 × 106 MSCs+, and surprisingly, MSCs−
(3 × 106 and 9 × 106 cell doses) were the only treatments that dually
caused functional recovery and a reduction in infarct volume.
HEK 293 cells arewidely used in in vitro cell studies because they are
easy to handle, grow rapidly, are resistant to stressful conditions, and
can be readily transfected [42]. Therefore, this cell line represented an
excellent model to test the effect of EAAT2 cell expression on blood glu-
tamate reduction. The functional improvement observed in ischemic
animals treated with HEK+ cells confirmed that this effect was indeed
mediated by the glutamate-grabbing activity associated with EAAT2
functionality.
The administration of HEK+ cells and oxaloacetate in ischemic ani-
mals resulted in almost similar glutamate reductions. However, the pro-
tective effect was quite different. This suggests that, in addition to the
obvious blood glutamate-grabbing effect, oxaloacetate may induce a
pleiotropic mechanism protecting the animal against ischemic stroke.
Oxaloacetate has been shown to serve as an antioxidant when cells
are subjected to stressful stimuli, such as hydrogen peroxide, thiobarbi-
turic acid reactive species, or excitotoxic damage [15].
MSCs are currently the most promising candidates for stem cell
therapy against ischemic stroke owing to their intrinsic capability to
secrete growth factors and immunomodulatory cytokines, which
equip these cells with neuroprotective and neurorecovery properties
[32]. Therefore, we hypothesized that the addition of a glutamate-
grabbing property should increase the protective effect of MSCs
against cerebral ischemia. The expression of EAAT2 in MSCs effectively
conferred the expected glutamate-grabbing activity validated in
healthy and ischemic animals. Unexpectedly, the protective effect ob-
served on infarct volume reduction and functional recovery after
MSC+ administration was not as pronounced as with MSCs−. This
finding suggests that the transfection procedure most likely interferes
with some of the intrinsic protective mechanisms of mesenchymalFig. 6. EAAT2–cell-based glutamate-grabbing therapy in ischemic rat models. (A) Effect of the d
animals. Data are shown as %± SD relative to the basal levels (*p b 0.05, **p b 0.01 comparedw
100% value of basal glutamate levels. (B) RepresentativeMRI of each experimental group at diffe
imaging at 1, 7, and 14 days. ADCmaps were used to determine the basal ischemic lesion before
time-points in ischemic animals. Data are shown as % ± SD relative to the ischemic hemisphe
group). The dashed line represents the infarct volume at 14 days after surgery of the control g
points in ischemic animals. Data are shown as % ± SD compared with the basal group (vehicle
the functional deficit of the control group (vehicle) at 14 days after stroke. Non-transfected M
HEK cells (HEK+), middle cerebral artery occlusion (MCAO), oxaloacetate (Oxal). (E) Histolog
of animals from each experimental group at 14 days after ischemic lesion in the cortical regio
cortical ischemic region. Magnification (400×). Scale bar, 50 μm. Data are shown as mean ±
transfected HEK cells (HEK−), transfected HEK cells (HEK+), oxaloacetate (Oxal), neurons (Necells. We could exclude the effect of the transfection procedure on
the release of VEGF and membrane phenotype. The quantification of
IL-6 secretion, which is considered one of the most representative
cytokines [34], in MSC supernatants revealed that the electroporation
procedure rather than plasmid expression induced the release of this
cytokine. This might explain the loss of the beneficial effect with
MSCs+ that we observed with MSCs. In fact, MSCs electroporated
with control plasmids (sham MSCs) were not included as an addi-
tional group in the animal study mainly because wanted to compare
the behavior of MSCs+ with that of healthy MSCs.
That MSCs release IL-6 upon LPS stimulation or other stressful stim-
uli like H2O2 [43] is well-documented [44]. However, there are conflict-
ing reports on the potential effects of this cytokine in stroke. Some
studies have found that the external administration of IL-6 in ischemic
animal models leads to an improvement in the animal outcome [45],
while we recently reported IL-6 to be associated with poor outcome in
a study on 4112 stroke patients [46], a finding that is corroborated by
the present findings.We cannot exclude that an alteration in the release
of other mesenchymal factors or cytokines could contribute to reduce
the beneficial effect of transfected MSCs in ischemic animals. From our
study, we can deduce that the experimentalmanipulation ofmesenchy-
mal cells induces an alteration of their intrinsic properties and reduces
their beneficial properties,which is an important issue for studies focus-
ing on the therapeutic effects of MSCs.
We previously evaluated the fate and biodistribution of MSCs after i.
v. administration in the same ischemic animalmodel aswe have used in
this study [30]. We observed that the benefits observed after i.v. deliv-
ery of MSCs were not attributable to the cell engraftment in the brain
as MSCs did not reach the brain tissue, and positively labeled cells
were found to be distributed mainly along the lungs. Therefore, we
can assume that the effect of MSCs on glutamate and infarct reduction
was mediated by a systemic effect and not the engraftment and dedif-
ferentiation into cerebral EAAT2-expressing cells, as astrocytes or endo-
thelial cells.
This study had some limitations that should be taken into consider-
ation. One of the main limitations of protective drugs against glutamate
excitotoxicity after stroke is the narrow therapeutic time window,
mainly because the increase in glutamate release appears immediately
after stroke; therefore, treatments against glutamate excitotoxicity
should be administered as soon as possible but within a clinically rele-
vant timewindow. In this study, cell infusionswere applied upon reper-
fusion, only 75 min after occlusion onset. This could be considered an
early treatment regimen, which might be impractical in the clinic set-
ting. However, although the metabolic rate in rats is faster than that in
humans (~6.4 times faster [47]), making the time window clinically ac-
ceptable, further studies should determine the time window of these
cell therapies.
In summary, our results show that cell-based therapies using the
administration of EAAT2-expressing cells to ischemia-lesioned
animal models is a novel alternative to reduce glutamate neuronal
excitotoxicity. Although further studies are necessary to optimize the
EAAT2 expression in mesenchymal cells, this study opens up avenues
for combining a protective strategy with a cell therapy for cerebral
ischemia.ifferent treatments on blood glutamate concentration at different time-points in ischemic
ith the control group at the same time-point; n= 6/group). The dashed line represents the
rent time-points. ADCmapswere determined during ischemia induction and T2-weighted
treatment administration. (C) Effect of the different treatments on infarct size at different
re (*p b 0.05, **p b 0.01 compared with the control group at the same time-point; n = 6/
roup (vehicle). (D) Functional analysis determined by the cylinder test at different time-
) at the same time-point (*p b 0.05, **p b 0.01; n = 6/group). The dashed line represents
SCs (MSCs−), transfected MSCs (MSCs+), non-transfected HEK cells (HEK−), transfected
ical analysis of neurons (NeuN, red), astrocytes (GFAP, green), and nuclei (Hoechst, blue)
n. (F) Quantification of GFAP-positive cells/mm2 and (G) NeuN-positive cells/mm2 in the
SD (n = 3/group). Non-transfected MSCs (MSCs−), transfected MSCs (MSCs+), non-
uN), glial fibrillary acidic protein (GFAP).
Fig. 7. In vitro and in vivo determination of the release of IL-6. (A) In vitro IL-6 quantities in the supernatants ofMSC− andMSC+ cultures under basalMSCs is associatedwith a release of IL-
6 conditions 24 h after transfection (with and without plasmid), and 48 h after LPS treatment for 24 h. Data are shown as mean ± SD (***p b 0.001, n = 9). The plasmid encoding the
fluorescent protein eGFP (pmaxGFP) was used as the control. pEAAT2 represents the YFP-EAAT2-encoding construct (B) Serum levels of IL-6 in ischemic rats treated with vehicle, 9
× 106 MSCs−, and 9 × 106 MSCs+. Data are shown as mean ± SD (**p b 0.01, n = 3). Non-transfected MSCs (MSCs−); transfected MSCs (MSCs+); lipopolysaccharide (LPS).
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